Latest Breaking News On - Newtyn management - Page 3 : comparemela.com

Bolt Biotherapeutics, Inc (NASDAQ:BOLT) Shares Sold by Vivo Capital LLC

Bolt Biotherapeutics, Inc (NASDAQ:BOLT) Shares Sold by Vivo Capital LLC
dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.

Newtyn managementHoldings channelVivo capitalBolt biotherapeutics incFree reportGet free reportVisit holdingschannel

Stock Traders Purchase High Volume of Call Options on Mersana Therapeutics (NASDAQ:MRSN)

Stock Traders Purchase High Volume of Call Options on Mersana Therapeutics (NASDAQ:MRSN)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Mersana therapeutics incWalleye capitalMerck kgaAsana biosciencesMerck kgaaAcadian asset managementAffinity asset advisorsJanssen biotech incClarivest asset managementJpmorgan chase coNewtyn managementMersana therapeuticsGet free reportAsset advisorsVest asset managementJanssen biotech

Vivo Capital LLC Sells 350,000 Shares of Bolt Biotherapeutics, Inc (NASDAQ:BOLT)

Vivo Capital LLC Sells 350,000 Shares of Bolt Biotherapeutics, Inc (NASDAQ:BOLT)
tickerreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tickerreport.com Daily Mail and Mail on Sunday newspapers.

Securities exchange commissionVivo capitalNewtyn managementBolt biotherapeutics incFree reportGet free report

Adverum Biotechnologies (NASDAQ:ADVM) Research Coverage Started at HC Wainwright

HC Wainwright initiated coverage on shares of Adverum Biotechnologies (NASDAQ:ADVM – Free Report) in a report issued on Tuesday morning, Marketbeat reports. The brokerage issued a buy rating and a $30.00 target price on the biotechnology company’s stock. HC Wainwright also issued estimates for Adverum Biotechnologies’ Q1 2024 earnings at ($1.23) EPS, Q2 2024 earnings […]

James paul scopaAdverum biotechnologieNewtyn managementCitigroup incCapital managementAdverum biotechnologies incAdverum biotechnologies company profileAdverum biotechnologiesFree reportModerate buyGet free reportDirector james paul scopaAsset managementApexium financialAdverum biotechnologies dailyNasdaq advm

Adverum Biotechnologies (NASDAQ:ADVM) Price Target Lowered to $22 00 at Mizuho

Adverum Biotechnologies (NASDAQ:ADVM – Free Report) had its target price trimmed by Mizuho from $40.00 to $22.00 in a report issued on Monday morning, Benzinga reports. The brokerage currently has a buy rating on the biotechnology company’s stock. A number of other research analysts also recently issued reports on the company. StockNews.com raised Adverum Biotechnologies […]

James paul scopaAdverum biotechnologies company profileCapital managementAdverum biotechnologies incNewtyn managementSecurities exchange commissionCitigroup incAdverum biotechnologiesFree reportModerate buyGet free reportDirector james paul scopaExchange commissionAsset managementApexium financialAdverum biotechnologies daily